Skip to main content

NASDAQ:ALBO - Albireo Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $72.00
  • Forecasted Upside: 140.80 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$29.90
▲ +0.49 (1.67%)
1 month | 3 months | 12 months
Get New Albireo Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALBO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALBO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$72.00
▲ +140.80% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Albireo Pharma in the last 3 months. The average price target is $72.00, with a high forecast of $82.00 and a low forecast of $65.00. The average price target represents a 140.80% upside from the last price of $29.90.

Buy

The current consensus among 8 polled investment analysts is to buy stock in Albireo Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/26/2021Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$79.00 ➝ $82.00High
i
3/8/2021Piper SandlerBoost Price TargetOverweight$68.00 ➝ $81.00Medium
i
3/1/2021Piper SandlerBoost Price TargetOverweight$68.00 ➝ $81.00Low
i
3/1/2021Robert W. BairdReiterated RatingBuy$67.00Low
i
12/18/2020HC WainwrightBoost Price TargetBuy$67.00 ➝ $75.00High
i
Rating by Ed Arce at HC Wainwright
11/19/2020WedbushReiterated RatingBuy$66.00Low
i
9/18/2020WedbushReiterated RatingBuy$62.00High
i
9/10/2020CowenBoost Price Target$39.00 ➝ $65.00Medium
i
9/8/2020Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$50.00 ➝ $79.00High
i
9/8/2020Needham & Company LLCBoost Price TargetBuy$50.00 ➝ $68.00High
i
Rating by Alan Carr at Needham & Company LLC
9/8/2020HC WainwrightBoost Price TargetPositive ➝ Buy$50.00 ➝ $67.00High
i
Rating by Ed Arce at HC Wainwright
9/8/2020Piper SandlerBoost Price TargetOverweight$45.00 ➝ $81.00High
i
8/19/2020HC WainwrightLower Price TargetBuy$64.00 ➝ $50.00High
i
Rating by Ed Arce at HC Wainwright
8/10/2020William BlairReiterated RatingBuyLow
i
7/30/2020Piper SandlerInitiated CoverageOverweight$45.00High
i
7/28/2020Needham & Company LLCReiterated RatingBuy$50.00Medium
i
Rating by Alan Carr at Needham & Company LLC
7/27/2020CowenReiterated RatingOutperform$39.00Medium
i
7/16/2020HC WainwrightBoost Price TargetBuy$62.00 ➝ $64.00Medium
i
6/24/2020Robert W. BairdInitiated CoverageOutperform$52.00High
i
6/17/2020WedbushReiterated RatingOutperformHigh
i
6/16/2020Needham & Company LLCInitiated CoverageBuy$50.00Medium
i
Rating by Alan Carr at Needham & Company LLC
6/14/2020HC WainwrightReiterated RatingBuy$62.00Medium
i
5/11/2020WedbushReiterated RatingBuy$60.00High
i
5/7/2020Needham & Company LLCInitiated CoverageBuy$50.00High
i
Rating by Alan Carr at Needham & Company LLC
4/5/2020HC WainwrightReiterated RatingBuy$62.00High
i
3/5/2020CowenReiterated RatingBuy$39.00Low
i
3/3/2020HC WainwrightReiterated RatingBuy$62.00High
i
3/3/2020WedbushLower Price TargetOutperform$69.00 ➝ $60.00High
i
1/30/2020HC WainwrightReiterated RatingBuy$62.00High
i
Rating by Ed Arce at HC Wainwright
11/6/2019CowenReiterated RatingBuy$39.00Low
i
11/6/2019WedbushReiterated RatingBuy$69.00Low
i
Rating by Liana Moussatos at Wedbush
8/11/2019HC WainwrightReiterated RatingBuy$62.00Medium
i
Rating by E. Arce at HC Wainwright
8/9/2019WedbushReiterated RatingOutperform$69.00High
i
Rating by Liana Moussatos at Wedbush
7/15/2019William BlairReiterated RatingBuyLow
i
Rating by Tim Lugo at William Blair
7/11/2019WedbushSet Price TargetBuy$69.00Medium
i
Rating by Liana Moussatos at Wedbush
7/10/2019HC WainwrightReiterated RatingBuy$62.00High
i
Rating by E. Arce at HC Wainwright
5/23/2019WedbushSet Price TargetBuy$69.00Low
i
Rating by Liana Moussatos at Wedbush
5/9/2019William BlairReiterated RatingOutperformHigh
i
Rating by T. Lugo at William Blair
4/17/2019CowenReiterated RatingBuyHigh
i
3/10/2019WedbushSet Price TargetBuy$69.00High
i
Rating by Liana Moussatos at Wedbush
2/28/2019HC WainwrightInitiated CoverageBuy ➝ Buy$62.00High
i
Rating by E. Arce at HC Wainwright
1/25/2019WedbushReiterated RatingBuy$69.00Low
i
Rating by Liana Moussatos at Wedbush
11/14/2018CowenReiterated RatingBuyMedium
i
11/13/2018Needham & Company LLCReiterated RatingBuy$50.00Low
i
10/17/2018WedbushReiterated RatingBuy$69.00Medium
i
Rating by Liana Moussatos at Wedbush
8/8/2018CowenReiterated RatingBuyHigh
i
8/7/2018WedbushReiterated RatingOutperform$69.00Low
i
Rating by L. Moussatos at Wedbush
7/16/2018WedbushReiterated RatingOutperformLow
i
Rating by L. Moussatos at Wedbush
6/12/2018WedbushReiterated RatingOutperform$69.00Medium
i
4/20/2018WedbushReiterated RatingOutperform$63.00Low
i
4/20/2018Jefferies Financial GroupInitiated CoverageBuy$50.00High
i
3/28/2018WedbushReiterated RatingOutperform$63.00Medium
i
3/15/2018Needham & Company LLCInitiated CoverageBuy$50.00High
i
2/2/2018Needham & Company LLCBoost Price TargetBuy$50.00Low
i
1/19/2018WedbushReiterated RatingBuyLow
i
1/3/2018WedbushReiterated RatingBuyHigh
i
11/17/2017CowenReiterated RatingBuyN/A
i
11/15/2017Roth CapitalInitiated CoverageBuy ➝ Buy$92.00N/A
i
Rating by Y. Rahimi at Roth Capital
10/26/2017Needham & Company LLCReiterated RatingBuyN/A
i
9/11/2017WedbushReiterated RatingOutperform$58.00Low
i
Rating by L. Moussatos at Wedbush
8/16/2017CowenInitiated CoverageOutperformHigh
i
7/18/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$35.00High
i
6/30/2017WedbushInitiated CoverageOutperformHigh
i
Rating by L. Moussatos at Wedbush
2/16/2017LADENBURG THALM/SH SHInitiated CoverageBuyN/A
i
1/25/2017William BlairInitiated CoverageOutperformN/A
i
Rating by Y. Xu at William Blair
(Data available from 5/16/2016 forward)
Albireo Pharma logo
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $29.90
$29.52
$30.81

50 Day Range

MA: $32.46
$28.90
$35.48

52 Week Range

Now: $29.90
$22.08
$49.00

Volume

197,931 shs

Average Volume

173,393 shs

Market Capitalization

$573.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Albireo Pharma?

The following Wall Street analysts have issued reports on Albireo Pharma in the last year: Cowen Inc, HC Wainwright, Jefferies Financial Group Inc., Needham & Company LLC, Piper Sandler, Robert W. Baird, Wedbush, William Blair, and Zacks Investment Research.
View the latest analyst ratings for ALBO.

What is the current price target for Albireo Pharma?

7 Wall Street analysts have set twelve-month price targets for Albireo Pharma in the last year. Their average twelve-month price target is $72.00, suggesting a possible upside of 140.8%. Jefferies Financial Group Inc. has the highest price target set, predicting ALBO will reach $82.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $65.00 for Albireo Pharma in the next year.
View the latest price targets for ALBO.

What is the current consensus analyst rating for Albireo Pharma?

Albireo Pharma currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALBO will outperform the market and that investors should add to their positions of Albireo Pharma.
View the latest ratings for ALBO.

What other companies compete with Albireo Pharma?

How do I contact Albireo Pharma's investor relations team?

Albireo Pharma's physical mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company's listed phone number is (857) 254-5555 and its investor relations email address is [email protected] The official website for Albireo Pharma is www.albireopharma.com.